Immunoediting and persistence of antigen-specific immunity in patients who have previously been vaccinated with NY-ESO-1 protein formulated in ISCOMATRIX™.
about
Serum cytokine profiles associated with specific adjuvants used in a DNA prime-protein boost vaccination strategy.NY-ESO-1 cancer testis antigen demonstrates high immunogenicity in triple negative breast cancer.Regression of devil facial tumour disease following immunotherapy in immunised Tasmanian devils.New insights into cancer immunoediting and its three component phases--elimination, equilibrium and escapeImmunomodulatory action of the DNA methyltransferase inhibitor SGI-110 in epithelial ovarian cancer cells and xenografts.Mismatch in epitope specificities between IFNγ inflamed and uninflamed conditions leads to escape from T lymphocyte killing in melanoma.Adaptive immune responses associated with breast cancer relapse.Update on vaccines for high-risk melanoma.The immune system and cancer evasion strategies: therapeutic concepts.Cancer testis antigen and immunotherapy.NY-ESO-1 specific antibody and cellular responses in melanoma patients primed with NY-ESO-1 protein in ISCOMATRIX and boosted with recombinant NY-ESO-1 fowlpox virus.Synthetic nanovaccines for immunotherapy.Development of a novel, quantitative protein microarray platform for the multiplexed serological analysis of autoantibodies to cancer-testis antigens.Modulating the immune system through nanotechnology.Enhancing tumor specific immune responses by transcutaneous vaccination.Oncolysate-loaded Escherichia coli bacterial ghosts enhance the stimulatory capacity of human dendritic cells.Blockade of CTLA-4 promotes the development of effector CD8+ T lymphocytes and the therapeutic effect of vaccination with an attenuated protozoan expressing NY-ESO-1.Adjuvant NY-ESO-1 vaccine immunotherapy in high-risk resected melanoma: a retrospective cohort analysis.Low-dose cyclophosphamide enhances antigen-specific CD4+ T cell responses to NY-ESO-1/ISCOMATRIX™ vaccine in patients with advanced melanomaTurn Back the TIMe: Targeting Tumor Infiltrating Myeloid Cells to Revert Cancer Progression
P2860
Q31138173-2555F089-52C9-44B2-9D7E-BF3FCCBAA7D4Q34325790-9530C346-48F1-4954-83EC-D9CAD5494221Q34552989-4A68F4F0-8D54-45FF-B14A-E9153855473FQ35300077-C5FE2C62-0A39-4B9A-B001-C7CE8CA2944FQ36214731-22E8A9BC-A95E-4831-8E0E-998AF89758EDQ36583731-7290609E-598C-4397-9AE6-4B8ECF3F1313Q38036579-53C471BF-5283-4134-AC58-E493D5BB9AECQ38208715-72688FD5-5EE8-472C-9E43-2C183D7B31C5Q38691172-21F5DE7E-6068-40E6-AB1C-93AC6BB8B97AQ38912232-D430FFF0-BC20-4E59-8495-3B9122136821Q39150340-B8460D3B-1BBF-4C4B-A293-D2979C23F1A8Q40280801-6F673EF3-64B1-46E3-8201-20ACB40CC559Q42225195-76AC40E1-9913-404A-9280-DA1515B9A130Q48630939-FAEEB872-76FB-4744-A881-6997C072677FQ49932505-34206541-B7BC-466A-9381-1C28E46727FFQ50545957-96E1D413-E2D9-4040-9979-6928E8A09F3BQ50770388-0040A266-D9A5-4DD6-B2A6-29CDA4B4EEDFQ55136811-9A9CD905-EA69-4918-8406-F91F3E8A17E7Q57571845-902F54FA-F267-4622-B5EF-F221E779D3B7Q58780996-3A6239A4-8378-426C-B8CA-BC80BD084636
P2860
Immunoediting and persistence of antigen-specific immunity in patients who have previously been vaccinated with NY-ESO-1 protein formulated in ISCOMATRIX™.
description
2011 nî lūn-bûn
@nan
2011年の論文
@ja
2011年学术文章
@wuu
2011年学术文章
@zh
2011年学术文章
@zh-cn
2011年学术文章
@zh-hans
2011年学术文章
@zh-my
2011年学术文章
@zh-sg
2011年學術文章
@yue
2011年學術文章
@zh-hant
name
Immunoediting and persistence ...... ein formulated in ISCOMATRIX™.
@en
Immunoediting and persistence ...... ein formulated in ISCOMATRIX™.
@nl
type
label
Immunoediting and persistence ...... ein formulated in ISCOMATRIX™.
@en
Immunoediting and persistence ...... ein formulated in ISCOMATRIX™.
@nl
prefLabel
Immunoediting and persistence ...... ein formulated in ISCOMATRIX™.
@en
Immunoediting and persistence ...... ein formulated in ISCOMATRIX™.
@nl
P2093
P2860
P1476
Immunoediting and persistence ...... tein formulated in ISCOMATRIX™
@en
P2093
Catherine Barrow
David Williams
Duncan Macgregor
Eric W Hoffman
Eugene Maraskovsky
Heather M Jackson
Ian D Davis
Judy Browning
Lloyd J Old
P2860
P2888
P304
P356
10.1007/S00262-011-1041-3
P577
2011-06-23T00:00:00Z